CHINA BIOLOGIC PRODUCTS INC
Latest Quote @ Wed Jun 6 01:19:17 (15 min delayed)
Last Day's Data
China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; prevention and cure of low-density-lipoproteinemia; and Neonatal hyperbilirubinemia. The company also provides Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection as a cure for various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and various cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it offers Human Rabies Immunoglobulin for passive immunity from bites or claws by rabies, or other infected animals; and Human Tetanus Immunoglobulin for the prevention and therapy of tetanus. The companyÃ¢Â€Â™s products under development include Human Prothrombin Complex Concentrate, Human Coagulation Factor VIII, Human Hepatitis B Immunoglobulin (PH4) for intravenous injection, Human Fibrinogen, Varicella Hyperimmune Globulins, and Human Immunoglobulin for intravenous injection. It sells its products primarily to hospitals and inoculation centers through distributors. The company was founded in 1971 and is based in Taian City, the People's Republic of China.